Clinical Trials in Detroit

Showing 11421-11440 of 16,931 trials

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT02138812

Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.

Medical Oncology

Bayer69 participantsStarted May 2014

Santa Monica, California, United States • New Haven, Connecticut, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 1< 1 mile

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

NCT02319018

This phase I trial studies the side effects and best dose of alisertib when given together with combination chemotherapy in treating patients with gastrointestinal tumors. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving alisertib with more than one drug (combination chemotherapy) may be a better treatment for gastrointestinal tumors.

Malignant Digestive System Neoplasm

National Cancer Institute (NCI)14 participantsStarted Aug 2015

New Haven, Connecticut, United States • New Haven, Connecticut, United States • Baltimore, Maryland, United States +2 more locations

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Find Trials by Condition in Detroit

Substance Abuse Treatment to HIV Care (SAT2HIV): The Implementation & Sustainment Facilitation Experiment

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Reducing Inappropriate Benzodiazepine Use Among Older Adults

Sevelamer for Reducing Endotoxemia and Immune Activation

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Post-Market Study of the Modular Revision Hip System

Gastric Electrical Stimulation (GES) for the Treatment of Obesity

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study